



IFW

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)			Docket No.	
Applicant(s): Dawei Chen et al.			API-0002	
Application No. 10/716,175	Filing Date 11/18/2003	Examiner C. Aulakh	Customer No. 23413	Group Art Unit 1625
Invention: SUBSTITUTED ARYL INHIBITORS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION				
<div style="text-align: center;"></div>				
<p>I hereby certify that this (See details below) _____ (Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on January 18, 2006 (Date)</p> <div style="text-align: right;"><p>Janice Young-Astwood (Typed or Printed Name of Person Mailing Correspondence)</p><p> (Signature of Person Mailing Correspondence)</p></div>				
<p>Note: Each paper must have its own certificate of mailing.</p>				
<div style="border: 1px solid black; padding: 10px;"><p>Transmittal of IDS (2 pgs) Supplemental IDS (4 pgs) Form PTO-A820 (PTO-1449) (7 pgs) Cited References (61) Return Receipt Postcard</p></div>				

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
API-0002

In Re Application Of: **Dawei Chen et al.**

Application No. 10/716,175	Filing Date 11/18/2003	Examiner C. Aulakh	Customer No. 23413	Group Art Unit 1625	Confirmation No. 3903
--------------------------------------	----------------------------------	------------------------------	------------------------------	-------------------------------	---------------------------------

Title: **SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

API-0002

In Re Application of: Dawei Chen et al.

Application No.

10/716,175

Filing Date

11/18/2003

Examiner

C. Aulakh

Customer No.

23413

Group Art Unit

1625

Confirmation No.

3903

Title: **SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 18, 2006

(Date)

Signature of Person Mailing Correspondence

Janice Young-Astwood

Typed or Printed Name of Person Mailing Certificate


***This certificate may only be used if paying by deposit account.**

Leslie Anne Horvath
Signature

Dated: January 18, 2006

Leslie-Anne Horvath, Ph.D.
Registration No.: 44,778
CANTOR COLBURN LLP
55 Griffin Road South
Bloomfield, CT 06002
Telephone: (860) 286-2929
Facsimile: (860) 286-0115

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dawei CHEN, et al.

Serial No.: 10/716,175

Filed: 11/18/03

For: SUBSTITUTED ARYL THIOUREAS AND
RELATED COMPOUNDS; INHIBITORS
OF VIRAL REPLICATION

)
) Group Art Unit: 1625
)
)
) Examiner: Charanjit AULAKH
)
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Dear Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publications and references. Copies of the non-United States patents or published applications are enclosed.

The filing of the current Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Some of the documents listed on attached Form PTO-1449 are not in English. In accordance with 37 C.F.R. §1.98(a)(3), applicants have provided below an explanation of the relevance of each listed publication that is not in the English language.

Applicants also draw the Examiner's attention to an IDS filed January 18, 2006, in co-pending U.S. Application No. 11/015,300, which claims priority from the current application.

English translations are provided in this IDS for certain documents previously submitted in a foreign language. These documents include:

(1) Mitin, N. I. et al., "Effect of Adamantine-containing Compounds on Aujeszky's and Avian Influenza Disease Viruses," Fiziologicheskii Aktivnye Veshchestva (1977) 9, 31-5. This document is in Russian and was submitted in IDS 1, filed April 21, 2004.

(2) Praceus, C. et al., "Inhibition of vaccinia virus in vitro by substituted monophenylthioureas," *Naturwissenschaften* (1964) 51(4), 94-5. This document is in German and was submitted in IDS 1, filed April 21, 2004.

(3) Schuster, G., "Structurally Dependent Effect of Substituted Thioureas on the Concentration of Potato Virus X in *Nicotiana tabacum* L." *Zentralblatt fuer Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene, Abteilung 2, Naturwissenschaftliche: Microbiologia der Landwirtschaft, der Technologie und des Umweltschutzes* (1978), 133(7-8), 686-9. This document is in German and was submitted in IDS 1, filed April 21, 2004.

(4) Reynaud, P., et al. "*p*-alcoxy benzoyl-1 *p*-alcoxyphényl-3 thiourées: leur activité <<in vitro>> et <<in vivo>> sur la souche H₃₇RV du bacille tuberculeux" *Chimie Thérapeutique* (1966), 7, 421-4. This document is in French and was submitted in IDS 3, filed July 15, 2004.

(5) Goerdeler, J., et al., "Substituierte Thiazolin-dione-(4.5) und ihre thermische Spaltung in Isocyanate und Senföle," *Chemische Berichte* (1966) 99(11), 3572-81. This document is in German and was submitted in IDS 3, filed July 15, 2004.

(6) Goerdeler, J., et al., "Das dualistische Verhalten von Carbamoyl-isothiocyanaten, I," *Liebigs Ann. Chem.* (1970) 731, 120-141. This document is in German and was submitted in IDS 3, filed July 15, 2004.

Applicants submit an English translation for each of these five publications with the current Information Disclosure Statement.

Publications Whose First Submission is by the Current Information Disclosure Statement


Certain publications cited in the current Information Disclosure Statement are not currently available in English. However, Applicants will obtain English translations of these documents at the request of the Office.

The current Information Disclosure Statement also includes publications discussed in U.S. Provisional Application No. 60/427,634 filed November 19, 2002, but not previously submitted in an Information Disclosure Statement. This application claim priority from U.S. Provisional Application No. 60/427,634.

(1) Baltabaev et al., Azerbaidzhanskii Kim. Zhur., *Synthesis of Nicotinylthiourea Derivatives*, 4: 97-99 (2000) is in Russian. An English translation is provided.


(2) JP 06003787 A2 is in Japanese. Applicants provide an English translation of the abstract of JP 06003787 A2 with the current Information Disclosure Statement. Applicants will provide further

translation of JP 06003787 A2 upon request by the U.S. Patent and Trademark Office. General formulas that are discussed include:




in which X may be a variety of bivalent linking groups.

(3) JP06287171 A2 is in Japanese. Applicants provide an English translation of the abstract of JP06287171 A2 with the current Information Disclosure Statement. Applicants will provide further translation of JP06287171 A2 upon request by the U.S. Patent and Trademark Office. General formulas that are discussed include:




(4) JP 11-335375 is in Japanese. An English machine translation is provided.

(5) WO 97/11050 is in Japanese with an English abstract. Applicants provide an English translation of the claims of WO 97/11050 with the current Information Disclosure Statement. Applicants will provide further translation of WO 97/11050 upon request by the U.S. Patent and Trademark Office. General formulas that are discussed include:




which in some instances includes compounds of the general formula:




(See, formula 1j, page 59).

(6) WO 03/099812 is in French with an English abstract. Applicants provide an English translation of the claims of WO 03/099812 with the current Information Disclosure Statement. Applicants will provide further translation of WO 03/099812 upon request by the U.S. Patent and Trademark Office. General formulas that are discussed include:



(7) WO 2004/020416 is in German with an English abstract. Applicants provide an English translation of the claims of WO 2004/020416 with the current Information Disclosure Statement. Applicants will provide further translation of WO 2004/020416 upon request by the U.S. Patent and Trademark Office. General formulas that are discussed include:



Respectfully submitted,
CANTOR COLBURN LLP

Date: January 18, 2006
Customer No. 23,413
(860) 286-2929

By: Leslie Anne Horvath
Leslie-Anne Horvath
Reg. No. 44,778

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number	10/716,175
Filing Date	11/18/2003
First Named Inventor	Dawei Chen et al.
Art Unit	1614
Examiner Name	C. Aulakh
Attorney Docket Number	API-0002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1.	3 966 968		06-29-1976	Andree et al.	
	2.	4 044 126		08-23-1977	Cook et al.	
	3.	4 350 706		09-21-1982	Brouwer et al.	
	4.	4 364 923		12-12-1982	Cook et al.	
	5.	4 414 209		11-08-1983	Cook et al.	
	6.	4 522 811		06-11-1985	Eppstein et al.	
	7.	4 868 215		09-19-1989	Bisabri-ershadi et al.	
	8.	5 001 266		03-19-1991	Rigterink et al.	
	9.	5 114 918		05-19-1992	Ishikawa et al.	
	10.	5 166 180		11-24-1992	Jenkins	
	11.	5 266 707		11-30-1993	Matsumoto et al.	
	12.	5 268 389		12-07-1993	Harrison et al.	
	13.	5 344 842		09-06-1994	Missbach	
	14.	5 424 204		06-13-1995	Aoyama et al.	
	15.	5 437 996		08-01-1995	Kojiri et al.	
	16.	5 449 812		09-12-1995	Schnabel et al.	
	17.	5 589 365		12-31-1996	Kojiri et al.	
	18.	5 591 842		01-07-1997	Kojiri et al.	
	19.	5 656 642		08-12-1997	Fujioka et al.	
	20.	5 693 827		12-02-1997	Harrison et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind ⁵ (if known)				
	21.	CA	2170222		08-28-1996	Bayer Aktiengesellschaft		
	22.	EP	0 518 376	A1	12-16-1992	Canon Kabushiki Kaisha		
	23.	EP	1 251 130	A1	10-23-2002	Kyowa Hakko Kogyo Co Ltd		
	24.	JP	06-003787	A2	01-14-1994	Konica Corp	Transl. of Abstract	X
	25.	JP	06-287171	A2	10-11-1994	Takeda Chem Ind. Ltd	Transl. of Abstract	X
	26.	JP	11-335375	A2	12-07-1999	Mitsui Chem Inc	Machine translation	X
	27.	WO	97/03976	A1	02-06-1997	Nissan Chemical Industries		
	28.	WO	97/11050	A1	03-27-1997	UBE Industries Ltd	Transl. of claims only	X
	29.	WO	97/30047	A1	08-21-1997	Agreva UK Limited		
	30.	WO	98/42323	A1	10-01-1998	Takeda Chemical Industries		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/716,175
				Filing Date	11/18/2003
				First Named Inventor	Dawei Chen et al.
				Art Unit	1614
				Examiner Name	C. Aulakh
Sheet	2	of	6	Attorney Docket Number	API-0002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			
	31.	5 723 409		03-03-1998	Schnabel et al.	
	32.	5 728 699		03-17-1998	Toriyabe et al.	
	33.	5 840 917		11-24-1998	Oi et al.	
	34.	5 849 666		12-15-1998	Kehne et al.	
	35.	5 874 615		02-23-1999	Verbrugge et al.	
	36.	5 922 740		07-13-1999	Braunlich et al.	
	37.	6 133 258		10-17-2000	Shishikura et al.	
	38.	6 138 826		10-24-2000	Fijioka et al.	
	39.	6 143 780		11-07-2000	Brouwer et al.	
	40.	6 169 092 B1		01-02-2001	Braunlich et al.	
	41.	6 174 905 B1		01-16-2001	Suzuki et al.	
	42.	6 177 074		01-23-2001	Glue et al.	
	43.	6 316 492		11-13-2001	Young et al.	
	44.	6 399 657 B1		06-04-2002	Braunlich et al.	
	45.	6 407 246		06-18-2002	Uckun et al.	
	46.	6 420 396 B1		07-16-2002	Albers et al.	
	47.	6 440 985		08-27-2002	Bailey et al.	
	48.	6 528 528 B2		03-04-2003	Connor et al.	
	49.	6 610 715 B1		08-26-2003	Youn et al.	
	50.	6 677 360 B1		01-13-2004	Albers et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Document Number			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office*	Number*	Kind* (if known)				
	51.	WO	99/59586	A1	11-25-1999	Regents of the Univ. of Calif		
	52.	WO	00/35864	A1	06-22-2000	Bayer Aktiengesellschaft		
	53.	WO	2003/037869	A1	05-08-2003	Janssen Pharmaceutica		
	54.	WO	2003/097604	A1	11-27-2003	Bayer Cropscience GmbH		
	55.	WO	2003/097605	A1	11-27-2003	Bayer Cropscience GmbH		
	56.	WO	2003/099812	A1	12-04-2003	Pierre Fabre Medicament	Transl. of claims only	X
	57.	WO	2004/020416	A2	03-11-2004	Bayer Cropscience GmbH	Transl. of claims only	X

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/716,175
				Filing Date	11/18/2003
				First Named Inventor	Dawei Chen et al.
				Art Unit	1614
				Examiner Name	C. Aulakh
Sheet	3	of	6	Attorney Docket Number	API-0002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	58.	6 677 372	B1	01-13-2004	Braulich et al.	
	59.	6 713 502	B2	03-30-2004	Dhanak et al.	
	60.	6 727 267	B2	04-27-2004	Jaen et al.	
	61.	6 736 336		05-18-2004	Wong	
	62.	6 770 666		08-03-2004	Hashimoto et al.	
	63.	6 780 873	B1	08-24-2004	Crooks et al.	
	64.	6 864 289	B1	03-08-2005	Tohnishi et al.	
	65.	2002/0099210	A1	07-25-2002	Alexander et al.	
	66.	2003/0109578	A1	06-12-2003	Braunlich et al.	
	67.	2003/0195231		10-16-2003	Takemoto et al.	
	68.	2004/0009982	A1	01-15-2004	Tohnishi et al.	
	69.	2004/0029877	A1	02-12-2004	Crooks et al.	
	70.	2004/0034041		02-19-2004	Dhanak et al.	
	71.	2004/0082635		04-29-2004	Hashimoto et al.	
	72.	2004/0097438		05-20-2004	Hashimoto et al.	
	73.	2004/0132727	A1	07-08-2004	Sakai et al.	
	74.	2004/0147535		01-22-2004	Crooks et al.	
	75.	2004/0147569		07-29-2004	Suzuki et al.	
	76.	2004/0147741		07-29-2004	Sundermann et al.	
	77.	2004/0162287	A1	08-19-2004	Sundermann et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Document Number			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office ³	Number ⁴	Kind ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet

4

of

6

Application Number

11/015,300

Filing Date

12/17/2004

First Named Inventor

Dawei Chen et al.

Art Unit

1614

Examiner Name

C. Aulakh

Attorney Docket Number

API-0002

[illegible][illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1449		Attorney's Docket Number API-0002	Serial Number 10/716,175
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <u>LIST OF ITEMS</u> (Use several sheets if necessary)		Name of Applicant Dawei Chen et al	
		Filing Date 11/18/2003	Group 1614
OTHER INFORMATION (including author, title, date, pertinent)			Translati on provided
	Alter, H.J. and Seeff, L.B., "Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: a Perspective on Long-Term Outcome," <i>Seminars in Liver Disease</i> , (2000) 20(1): 17-35.		
	Baltabaev, U.A. et al., "Synthesis of the Nicotinoylthioureas Compounds," <i>Azerbaidzhanskii Kim. Zhur.</i> , (2000) 4: 97-99		yes
	Baltabaev, U.A. et al., "Antiinflammatory Activity Of New Aryl- and Aroylthioureas," <i>Pharmaceutical Chemistry Journal</i> (2002) 36(2): 24-26.		
	Bartenschlager, R. "The NS3/4A Proteinase of the Hepatitis C Virus: Unravelling Structure and Function of an Unusual Enzyme and a Prime Target for Antiviral Therapy," <i>Journal of Viral Hepatitis</i> , (1999) 6:165-181.		
	Bressanelli, S. et al., "Crystal structure of the RNA-Dependent RNA Polymerase of Hepatitis C Virus," <i>Proceedings of the National Academy of Sciences, USA</i> , (1999) 96:13034-13039.		
	De Francesco, R. et al., "The Hepatitis C Virus NS3 Proteinase: Structure and Function of a Zinc-Containing Serine Proteinase," <i>Therapies for Viral Hepatitis</i> , (1998), pp. 235-245. Edited by R. F. Schinazi, J.-P. Sommadossi & H. C. Thomas. London: International Medical Press.		
	Douglass, I.B. and Forman, L.E. "Nicotinyl Isothiocyanate And Some Of Its Derivatives," <i>Journal of the American Chemical Society</i> (1934) 56(7): 1609		
	Du, X. et al., "Aryl Ureas Represent a New Class of Anti-Trypanosomal Agents," <i>Chemistry & Biology</i> (2000) 7(9): 733-742.		
	Esteban, J.I. et al., "The Clinical Picture of Acute and Chronic Hepatitis C," <i>Curr. Stud. Hematol. Blood Transf., Hepatitis C Virus</i> , (1998) 62: 102-118. Edited by W. Reesink. Basel, Switzerland: Karger.		
	Fukushi, S. et al., "Complete 5' Noncoding Region is Necessary for the Efficient Internal Initiation of Hepatitis C Virus RNA," <i>Biochemical and Biophysical Research Communications</i> , (1994) 199: 425-432.		
	Fukushi, S. et al., "The Sequence Element of the Internal Ribosome Entry Site and a 25-Kilodalton Cellular Protein Contribute to Efficient Internal Initiation of Translation of Hepatitis C Virus RNA," <i>Journal of Virology</i> , (1997) 71:1662-1666.		
	Goerdeler, J. and Jonas, K. "Über Thioacyl-isocyanate, V. Substituierte Thiazolin-dione-(4.5) und ihre Thermische Spaltung in Isocyanate und Senfole," <i>Chemische Berichte</i> (1966) 99(11): 3572-3581.		yes
	Goerdeler, J. and Wobig, D. "Das dualistische Verhalten von Carbamoyl-isothiocyanaten, I," <i>Liebigs Annalen Der Chem</i> (1970) 731: 120-141		yes
	Gwack, Y. et al., "Characterization of RNA Binding Activity and RNA Helicase Activity of the Hepatitis C Virus NS3 Protein," <i>Biochemical and Biophysical Research Communications</i> (1996) 225: 654-659.		
	Honda, M. et al., "Structural Requirements for Initiation of Translation by Internal Ribosome Entry within Genome-length Hepatitis C Virus RNA," <i>Virology</i> , (1996) 222: 31-42.		
	Iacovacci, S. et al., "Replication and mMtultiplication of Hepatitis C Virus Genome in Human Foetal Liver Cells," <i>Research in Virology</i> , (1993) 144: 275-279.		
	Khromykh, A.A. and Westaway, E.G., "Subgenomic Replicons of the Flavivirus Kunjin: Construction and Applications," <i>Journal of Virology</i> , (1997) 71: 1497-1505.		
	Kim, J.L. et al., "Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide," <i>Cell</i> , (1996) 87: 343-355.		
	Kim, J.L. et al., "Hepatitis C Virus NS3 RNA Helicase Domain with a Bound Oligonucleotide: the Crystal Structure Orovdes Insights into the Mode of Unwinding," <i>Structure</i> (1998) 6(1): 89-100.		

EXAMINER	DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.		

PTO-1449		Attorney's Docket Number API-0002	Serial Number 10/716,175
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <u>LIST OF ITEMS</u> (Use several sheets if necessary)		Name of Applicant Dawei Chen et al	
		Filing Date 11/18/2003	Group 1614
OTHER INFORMATION (including author, title, date, pertinent)			Translati on provided
	Koscik, D. et al., "New Synthesis of 2-Amino-4-oxopyrido[3,2-e]-1,3-thiazines and 1-Alkyl(aryl)pyrido[3,2-e]-2-thiouracils," <i>Collection Czechoslovak Chem. Comm.</i> (1983) 48: 3315-3328.		
	Lavanchy, D. et al., "Global Surveillance and Control of Hepatitis C," <i>Journal of Viral Hepatitis</i> (1999) 6: 35-47.		
	Lesburg, C.A. et al., "Crystal Structure of the RNA-Dependent RNA Polymerase from Hepatitis C Virus Reveals a Fully Encircled Active Site," <i>Nature Structural Biology</i> , (1999) 6: 937-943.		
	Liang, T.J. et al., "Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C," <i>Annals of Internal Medicine</i> (2000) 132: 296-305.		
	Lohmann, V. et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," <i>Science</i> (1999) 285: 110-113.		
	Love, R.A. et al., "The Crystal Structure of Hepatitis C Virus NS3 proteinase reveals a trypsin-like fold and a Structural zinc binding site," <i>Cell</i> (1996) 87:331-342.		
	Manns, M.P. et al., "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic Hepatitis C: a randomised trial," <i>Lancet</i> (2001):358:958-965.		
	McHutchison, J.G. et al., "Interferon Alfa-2b Alone or in Combination with fRibavirin as Initial Treatment for Chronic Hepatitis C," <i>New England Journal of Medicine</i> (1998) 339(21):1485-1492.		
	Mitin, N.I. et al., "Effect of Adamantyl-Containing Compounds on the viruses of False Rabies and Bird Flu", <i>Fiziologicheski Aktivnye Veshchestva</i> (1977) 9: 31-35		yes
	Moriya, K. et al., "The Core Protein of Hepatitis C Virus Induces Hepatocellular Carcinoma in Transgenic Mice," <i>Nature Medicine</i> (1998) 4:1065-1067.		
	Neumann, A.U. et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-Alpha Therapy," <i>Science</i> , (1998) 282: 103-107.		
	Nogrady, T. <i>Medicinal Chemistry A Biochemical Approach</i> , (1985) Oxford University Press, New York, pages 388-392		
	Patel, N.B. and Bhagat, P.R. "2-[4]-(p-Acetamidophenylcarbonyl) Piperazin-1"-yl]-3-(N-Aryl-Thioureidocarbonyl) Pyridines As Antibacterial Agents," <i>Indian Journal of Heterocyclic Chemistry</i> (2002) 12: 83-84.		
	Patel, N.B. and Bhagat, P.R. "Antibacterial Study of 2-(p-Tolyl Sulfonamido)-3-(N-Arylthioureido Carbonyl) Pyridine Derivatives" <i>Oriental Journal of Chemistry</i> (2002) 18(3): 551-554.		
	Praceus, Chr. et al., "Inhibition of Vaccinia Virus In Vitro By Substituted Monophenylthioureas," <i>Naturwissenschaften</i> (1964) 51(4): 94-95.		yes
	Reynaud, P. et al., "P-alcoxy Benzoyl-1 p-Alcoxyphenyl-3 thioureas: Their Activity "In Vitro" and "In Vivo" on the H ₃₇ RV of the Tubercular Bacillus," <i>Chimie Therapeutique</i> (1966) 7: 421-424. (machine translation)		yes
	Santolini, E. et al., "Biosynthesis and Biochemical Properties of the Hepatitis C Virus Core Protein," <i>Journal of Virology</i> (1994) 68: 3631-3641.		
	Schuster, G. "Structurally Dependent Effects of Substituted Thioureas on the Concentration of Potato Virus X in Nicotiana tabacum L," <i>Zbl. Bakt. II, Dep.</i> (1978) 133(7-8): 686-689.		yes
	Simmonds, P. et al., "Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region," <i>Journal of General Virology</i> (1993) 74:2391-2399.		
	Stempniak, M. et al., "The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme," <i>Journal of Virology</i> (1997) 71:2881-2886.		
	Tanaka, T. et al., "Structure of the 3' terminus of the hepatitis C virus genome," <i>Journal of Virology</i> (1996) 70:3307-3312.		
	Tsukiyama-Kohara, K. et al., "Internal ribosome entry site within hepatitis C virus RNA," <i>Journal of Virology</i> , (1992) 66:1476-1483.		
EXAMINER		DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.			

EXAMINER	DATE CONSIDERED	
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.</p>		